Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection?

doi:10.3748/wjg.v24.i9.971

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10976)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

666

WORD

318

HTML

5411

Figures (1-4)

262

Tables (1-6)

167

Sum=6824

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

856

Download

821

Sum=1677

Publishing Process of This Article

Item

Count

Browse

1090

Download

1385

Sum=2475

Mar 7, 2018 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Mar 7, 2018; 24(9): 971-981
Published online Mar 7, 2018. doi: 10.3748/wjg.v24.i9.971

Table 1 Polymerase chain reaction primers used in this study

Primer	Primer sequence	Gene	Product size (bp)
CAGA-F	5’-GATAACAGGCAAGCTTTTGATG-3’	cagA	349
CAGA-R	5’-CTGCAAAAGATTGTTTGGCAGA-3’	cagA	349
VA1-F	5’- ATGGAAATACAACAACAAACACAC-3’	vacA signal region	259/286 (s1/s2)
VA1-R	5’ – CTGCTTGAATGCGCCAAAC-3’	vacA signal region	259/286 (s1/s2)
VAG-F	5’ – CAATCTGTCCAATCAAGCGAG-3’	vacA middle region	567/642 (m1/m2)
VAG-R	5’- GCTTCAAAATAATTCCAAGG-3’	vacA middle region	567/642 (m1/m2)

Table 2 Demographic and clinical characteristics of Helicobacter pylori-infected patients included in the study

	Number of gastric biopsy specimens n (%)
	All patients 165 (100)	Treatment Naïve 105 (63.6)	Previously treated 60 (36.4)
Gender
Female	69 (41.8)	31 (29.5)	38 (63.3)
Male	96 (58.2)	74 (70.5)	22 (36.7)
Age
mean ± SD	49.2 ± 15.8	50.3 ± 16.3	47.4 ± 14.7
Histology findings
Chronic gastritis	130 (78.8)	78 (74.3)	52 (86.7)
Intestinal metaplasia	23 (13.9)	16 (15.2)	7 (11.7)
No data available	11 (6.7)	10 (9.5)	1 (1.7)
Normal mucosa	1 (0.6)	1 (1.0)	0 (0.0)
Endoscopic findings
Gastritis	92 (55.8)	57 (54.3)	35 (58.3)
Normal	32 (19.4)	19 (18.1)	13 (21.7)
Gastric/duodenal ulcer	21 (12.7)	15 (14.3)	6 (10.0)
No data available	17 (10.3)	11 (10.5)	6 (10.0)
Atrophic mucosa	1 (0.6)	1 (1.0)	0 (0.0)
Other¹	2 (1.2)	2 (1.9)	0 (0.0)

¹Other endoscopic findings: 1 intestinal metaplasia and erosion: 1 portal hypertensive gastropathy.

Table 3 Clarithromycin resistance rates and the distribution of resistance-mediating mutations

Genotype	Number of gastric biopsy specimens n (%)			P value¹
Genotype	All patients 165 (100)	Treatment Naïve 105 (63.6)	Previously treated 60 (36.4)	P value¹
Clarithromycin^S (WT)	65 (39.4)	52 (49.5)	13 (21.7)	< 0.001
Clarithromycin^R	100 (60.6)	53 (50.5)	47 (78.3)	< 0.001
Point mutations
A2147G	78 (78)	44 (83)	34 (72.3)	NS
A2146G	8 (8)	3 (5.7)	5 (10.6)	NS
A2146C	6 (6)	3 (5.7)	3 (6.4)	NS
A2146C + A2147G	5 (5)	3 (5.7)	2 (4.3)	NS
A2146G + A2147G	2 (2)	0 (0)	2 (4.3)	NS
A2146G + A2146C	1 (1)	0 (0)	1 (2.1)	NS

¹Treatment-naïve versus previously treated patients (Fisher’s exact test). Clarithromycin^S: Sensitive to clarithromycin; Clarithromycin^R: Resistant to clarithromycin.

Table 4 Fluoroquinolone resistance rates and the distribution of resistance-mediating mutations

Genotype	Number of gastric biopsy specimens n (%)			P value¹
Genotype	All patients 165 (100)	Treatment Naïve 105 (63.6)	Previously treated 60 (36.4)	P value¹
Fluoroquinolone^S (WT)	132 (80.0)	89 (84.8)	43 (71.7)
Fluoroquinolone^R	33 (20.0)	16 (15.2)	17 (28.3)	NS
Point mutations
gyr91 D91Y	18 (54.5)	10 (62.5)	8 (47.1)	NS
gyr91 D91N	6 (18.2)	2 (12.5)	4 (23.5)	NS
gyr91 D91G	2 (6.1)	0 (0.0)	2 (11.8)	NS
gyr91 D91N + gyr91 D91G	2 (6.1)	1 (6.3)	1 (5.9)	NS
gyr91 D91N +gyr91 D91Y	2 (6.1)	1 (6.3)	1 (5.9)	NS
gyr87 N87K	1 (3.0)	1 (6.3)	0 (0.0)	NS
gyr87 N87K + gyr91 D91N + gyr91 D91G	1 (3.0)	0 (0.0)	1 (5.9)	NS
gyr87 N87K + gyr91 D91N + gyr91 D91G + gyr91 D91Y	1 (3.0)	1 (6.3)	0 (0.0)	NS

¹Treatment-naïve versus previously treated patients (Fisher’s exact test). Fluoroquinolone^S: Sensitive to fluoroquinolones; Fluoroquinolone^R: Resistant to fluoroquinolones.

Table 5 Antimicrobial susceptibility results for both clarithromycin and fluoroquinolone

Genotype	Number of gastric biopsy specimens n (%)			P value¹
Genotype	All patients 165 (100)	Treatment Naïve 105 (63.6)	Previously treated 60 (36.4)	P value¹
Susceptible (to both)	60 (36.4)	49 (46.6)	11 (18.3)	< 0.05
Resistant (to at least one)	105 (63.6)	56 (53.3)	49 (81.6)	< 0.05
Susceptible/resistant to one	137 (83.0)	92 (87.6)	45 (75.0)
Resistant to both	28 (17.0)	13 (12.4)	15 (25.0)	0.05

¹Treatment-naïve versus previously treated patients (Fisher’s exact test).

Table 6 Distribution of Helicobacter pylori virulence-factor genotypes among infected patients in Ireland n (%)

Genotype	Overall (n = 165)	Treatment naïve (n = 105)	Previous treatment (n = 60)	P value¹
cagA status
Positive	37 (22.4)	25 (23.8)	12 (20)	NS
Negative	128 (77.6)	80 (76.2)	48 (80)
vacA allele
S1	113 (68.5)	78 (74.3)	35 (58.3)
S2	52 (31.5)	27 (25.7)	25 (41.7)	< 0.05
M1	47 (28.5)	31 (29.5)	16 (26.7)
M2	118 (71.5)	74 (70.5)	44 (73.3)	NS
S1/M1	39 (23.6)	26 (24.8)	13 (21.7)	NS
S1/M2	74 (44.8)	52 (49.5)	22 (36.7)	NS
S2/M1	8 (4.8)	5 (4.8)	3 (5.0)	NS
S2/M2	44 (26.7)	22 (21.0)	22 (36.7)	< 0.05

¹Treatment-naïve versus previously treated patients (Fisher’s exact test).

Citation: Brennan DE, Dowd C, O’Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? World J Gastroenterol 2018; 24(9): 971-981
URL: https://www.wjgnet.com/1007-9327/full/v24/i9/971.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i9.971